Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma

Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma

Bibliographic Details
Main Authors: Rakesh Popat, Bradley Augustson, Mercedes Gironella, Cindy Lee, Paul Cannell, Nashita Patel, Ravi S. Kasinathan, Rachel Rogers, Mehreen Shaikh, Amy Curry, Fernando Carreño, Sumita Roy-Ghanta, Joanna Opalinska, Hang Quach
Format: Article
Language:English
Published: Nature Publishing Group 2024-10-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-024-01155-y

Internet

https://doi.org/10.1038/s41408-024-01155-y

Similar Items